CN101522669B - 治疗用内酰胺 - Google Patents
治疗用内酰胺 Download PDFInfo
- Publication number
- CN101522669B CN101522669B CN2007800369601A CN200780036960A CN101522669B CN 101522669 B CN101522669 B CN 101522669B CN 2007800369601 A CN2007800369601 A CN 2007800369601A CN 200780036960 A CN200780036960 A CN 200780036960A CN 101522669 B CN101522669 B CN 101522669B
- Authority
- CN
- China
- Prior art keywords
- compound
- another embodiment
- phenyl
- alkyl
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*C(NS(*)(=*)=O)=O Chemical compound C*C(NS(*)(=*)=O)=O 0.000 description 14
- ULSRYYIJWPNBHG-UHFFFAOYSA-N CC(NS(c(cc1)ccc1[N+]([O-])=O)=O)=O Chemical compound CC(NS(c(cc1)ccc1[N+]([O-])=O)=O)=O ULSRYYIJWPNBHG-UHFFFAOYSA-N 0.000 description 1
- VXCYLVJOHXWNHD-UHFFFAOYSA-N CC(NS(c1cccc(Cl)c1)(=O)=O)=O Chemical compound CC(NS(c1cccc(Cl)c1)(=O)=O)=O VXCYLVJOHXWNHD-UHFFFAOYSA-N 0.000 description 1
- LXMDSJWRWDRKDS-DFJPGDIZSA-N CCCCCC(C1C=CC(N(C(COCC2SC(C(OC)=O)=CC2)[C@H](C2)O)C2=O)=CC1)O Chemical compound CCCCCC(C1C=CC(N(C(COCC2SC(C(OC)=O)=CC2)[C@H](C2)O)C2=O)=CC1)O LXMDSJWRWDRKDS-DFJPGDIZSA-N 0.000 description 1
- AVZSOLZDLIYMNT-IJHRGXPZSA-N CCCCCC(c(cc1)ccc1N(C(COCc1ccc(C(O)=O)[s]1)[C@H](C1)O)C1=O)=O Chemical compound CCCCCC(c(cc1)ccc1N(C(COCc1ccc(C(O)=O)[s]1)[C@H](C1)O)C1=O)=O AVZSOLZDLIYMNT-IJHRGXPZSA-N 0.000 description 1
- VYKWANDPGIGGGK-IPFXWSOASA-N CCCCCC(c(cc1)ccc1N([C@@H](COCc1ccc(C(O)=O)[s]1)CC1C)C1=O)O Chemical compound CCCCCC(c(cc1)ccc1N([C@@H](COCc1ccc(C(O)=O)[s]1)CC1C)C1=O)O VYKWANDPGIGGGK-IPFXWSOASA-N 0.000 description 1
- JAHCQVVOKAFXQU-UHFFFAOYSA-N CCCc1nnn[nH]1 Chemical compound CCCc1nnn[nH]1 JAHCQVVOKAFXQU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82210806P | 2006-08-11 | 2006-08-11 | |
| US60/822,108 | 2006-08-11 | ||
| PCT/US2007/075615 WO2008021975A2 (en) | 2006-08-11 | 2007-08-09 | Therapeutic lactams |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101522669A CN101522669A (zh) | 2009-09-02 |
| CN101522669B true CN101522669B (zh) | 2013-01-16 |
Family
ID=38683367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800369601A Expired - Fee Related CN101522669B (zh) | 2006-08-11 | 2007-08-09 | 治疗用内酰胺 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7482475B2 (OSRAM) |
| EP (1) | EP2066660A2 (OSRAM) |
| JP (1) | JP2010500416A (OSRAM) |
| KR (1) | KR101422305B1 (OSRAM) |
| CN (1) | CN101522669B (OSRAM) |
| AU (1) | AU2007286177B2 (OSRAM) |
| BR (1) | BRPI0716742A2 (OSRAM) |
| CA (1) | CA2660608A1 (OSRAM) |
| MX (1) | MX2009001578A (OSRAM) |
| NZ (1) | NZ597866A (OSRAM) |
| WO (1) | WO2008021975A2 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| CA2645867A1 (en) * | 2006-03-20 | 2007-09-27 | Allergan, Inc. | Substituted gamma lactams as prostaglandin ep2 agonists |
| EP2066660A2 (en) * | 2006-08-11 | 2009-06-10 | Allergan, Inc. | Therapeutic lactams |
| US7589213B2 (en) * | 2007-04-27 | 2009-09-15 | Old David W | Therapeutic substituted lactams |
| US8440819B2 (en) * | 2008-02-22 | 2013-05-14 | Allergan, Inc. | Therapeutic substituted beta-lactams |
| WO2009132088A1 (en) * | 2008-04-24 | 2009-10-29 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| JP6289470B2 (ja) * | 2012-08-21 | 2018-03-07 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 置換ガンマラクタムの合成方法 |
| US20150274658A1 (en) * | 2014-03-27 | 2015-10-01 | Allergan, Inc. | Therapeutic lactams |
| CA2979391C (en) | 2015-03-13 | 2023-10-17 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as hdac8 inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049577A (en) * | 1990-01-29 | 1991-09-17 | E. R. Squibb & Sons, Inc. | 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1991504A (en) * | 1928-09-12 | 1935-02-19 | American District Telegraph Co | Key-trapping valve lock for transmitter-supervised sprinkler systems |
| US5902726A (en) * | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
| CN1653046A (zh) | 2002-03-05 | 2005-08-10 | 小野药品工业株式会社 | 8－氮杂前列腺素衍生化合物以及包含该化合物作为活性成分的药物 |
| WO2004019938A1 (en) * | 2002-08-28 | 2004-03-11 | Merck Frosst Canada & Co. | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma |
| WO2006061366A1 (en) * | 2004-12-06 | 2006-06-15 | Laboratoires Serono S.A. | Pyrrolidin-2-one derivatives for use as dp1 receptor agonists |
| CN105520941B (zh) * | 2005-03-10 | 2020-05-01 | 阿勒根公司 | 作为治疗剂的取代的γ内酰胺 |
| CA2645867A1 (en) * | 2006-03-20 | 2007-09-27 | Allergan, Inc. | Substituted gamma lactams as prostaglandin ep2 agonists |
| EP2066660A2 (en) * | 2006-08-11 | 2009-06-10 | Allergan, Inc. | Therapeutic lactams |
-
2007
- 2007-08-09 EP EP07840832A patent/EP2066660A2/en not_active Withdrawn
- 2007-08-09 WO PCT/US2007/075615 patent/WO2008021975A2/en not_active Ceased
- 2007-08-09 KR KR1020097004976A patent/KR101422305B1/ko not_active Expired - Fee Related
- 2007-08-09 NZ NZ597866A patent/NZ597866A/xx not_active IP Right Cessation
- 2007-08-09 BR BRPI0716742 patent/BRPI0716742A2/pt not_active IP Right Cessation
- 2007-08-09 CA CA002660608A patent/CA2660608A1/en not_active Abandoned
- 2007-08-09 US US11/836,655 patent/US7482475B2/en active Active
- 2007-08-09 JP JP2009524741A patent/JP2010500416A/ja active Pending
- 2007-08-09 MX MX2009001578A patent/MX2009001578A/es active IP Right Grant
- 2007-08-09 AU AU2007286177A patent/AU2007286177B2/en not_active Ceased
- 2007-08-09 CN CN2007800369601A patent/CN101522669B/zh not_active Expired - Fee Related
-
2008
- 2008-12-15 US US12/334,704 patent/US8686025B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049577A (en) * | 1990-01-29 | 1991-09-17 | E. R. Squibb & Sons, Inc. | 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009001578A (es) | 2009-02-19 |
| AU2007286177A1 (en) | 2008-02-21 |
| NZ597866A (en) | 2013-08-30 |
| EP2066660A2 (en) | 2009-06-10 |
| KR20090038937A (ko) | 2009-04-21 |
| AU2007286177B2 (en) | 2012-06-14 |
| CA2660608A1 (en) | 2008-02-21 |
| WO2008021975A2 (en) | 2008-02-21 |
| WO2008021975A3 (en) | 2008-07-10 |
| US20080039505A1 (en) | 2008-02-14 |
| US7482475B2 (en) | 2009-01-27 |
| KR101422305B1 (ko) | 2014-07-22 |
| BRPI0716742A2 (pt) | 2015-03-24 |
| US8686025B2 (en) | 2014-04-01 |
| CN101522669A (zh) | 2009-09-02 |
| US20090099249A1 (en) | 2009-04-16 |
| JP2010500416A (ja) | 2010-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101522669B (zh) | 治疗用内酰胺 | |
| JP5532302B2 (ja) | 治療化合物 | |
| JP2010500976A (ja) | 治療用アミド類および関連化合物 | |
| US7795287B2 (en) | Therapeutic substituted hydantoins and related compounds | |
| JP5474548B2 (ja) | 治療用の置換チアゾリジノン類、オキサゾリジノン類および関連化合物 | |
| CA2653223C (en) | Therapeutic pyrrolidine compounds | |
| US7576112B2 (en) | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | |
| US7498447B2 (en) | Therapeutic compounds | |
| US7700627B2 (en) | Therapeutic substituted lactams | |
| US20150274658A1 (en) | Therapeutic lactams |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130116 Termination date: 20150809 |
|
| EXPY | Termination of patent right or utility model |